CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International…

By M. Pfreundschuh, E. Kuhnt, L. Trümper, A. Osterborg, M. Trněný, L. Shepherd, D. Gill, J. Walewski, R. Pettengell, U. Jaeger and 11 more. The Lancet Oncology, 2011

740 citations recorded by the source corpus.

Subfields: Neurology, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/41a3856f7884f7068aff7fe901b675a40fc5fff7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

H. Tilly
M. G. Silva
M. Meignan
U. Vitolo
L. Sehn
A. Jack
F. Morschhauser
J. Sharman

Citations in the corpus

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma (2021, background): “** An International Prognostic Index (IPI) score indicates low (0 or 1), low–intermediate (2), high–intermediate (3), or high (4 or 5) risk of a poor outcome on the basis of a scoring system that gives one point for each of the following risk factors: age older than 60 years, 1 or more extranodal ar”
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, methodology): “Six cycles of combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) treatment combined with six doses of rituximab given every 21 days is the current standard [I, A] [31].”